On May 8, Michael Yee, Senior Biotech Analyst at Jefferies, appeared on CNBC to discuss how tariffs and policy risks are pressuring the biotech industry, while simultaneously iterating that low ...

Angela Hwang spent nearly three decades at Pfizer before joining Flagship Pioneering in 2025 as a CEO-partner and the CEO of Metaphore Biotechnologies. In this week’s episode of "The Top Line ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Portage Biotech's PORT-7 showed >90% tumor growth inhibition with anti-PD1 combo in a murine mesothelioma model. PORT-7 single-agent activity outperformed anti-PD1 treatment alone; first-in-human ...

But today, Kendall has been reborn — as the glittering, glassy heart of America’s biotech industry. For many companies, Kendall Square’s status as a global center of biotechnology firms and ...

After San Francisco biotech company Third Harmonic Bio slashed its staff by half in February, it’s now taking a more drastic step. The inflammatory disease research company’s directors have ...

A biotech company says it has bred three animals with key physical features of the dire wolf — a species that has been extinct for more than 12,000 years. Colossal Biosciences says it used novel ...

Congress should invest at least $15 billion to support biotech research over the next five years and take other steps to bolster manufacturing in the U.S., while barring companies from working ...

Colossal Biosciences said it restored the long-extinct canine species. In a scientific breakthrough that could forever change how humans interact with our planet, Colossal Biosciences said it has ...

AmplifyBio, once one of central Ohio's most promising biotech firms, announced Friday that it has shut down. In a posting on its website, the company said the decision followed months of efforts ...

Biotech stocks sold off hard last month. Negative company-specific and sector-specific news roiled these high-risk, high-upside plays. HHS Secretary Robert F. Kennedy Jr. appears to be a big ...

There remains much uncertainty about these measures, however. As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news.